<?xml version="1.0" encoding="UTF-8"?>
<doi_batch version="4.4.0" xmlns="http://www.crossref.org/schema/4.4.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.crossref.org/schema/4.4.0 http://www.crossref.org/schema/deposit/crossref4.4.0.xsd">
<head>
<depositor>
<depositor_name>wkjm</depositor_name>
<email_address><span class="nowrap">Contact[[File:At sign.svg|alt=At sign|15px|@|link=]]WikiJMed.org</span></email_address>
</depositor>
<registrant>WEB-FORM</registrant>
</head>
<body>
<journal>
<journal_metadata>
<full_title>WikiJournal of Medicine/Anthracyclines</full_title>
<abbrev_title>Wiki.J.Med.</abbrev_title>
<issn media_type='electronic'>2002-4436 / 2470-6345 / 2639-5347</issn>
<doi_data>
<doi>10.15347/WJM</doi>
<resource>http://www.WikiJMed.org/</resource>
</doi_data>
</journal_metadata>
<journal_issue>
<publication_date media_type='online'>
<year>2018</year>
</publication_date>
<journal_volume>
<volume>5</volume>
</journal_volume>
<issue>1</issue>
</journal_issue>
<journal_article publication_type='full_text'>
<titles>
<title>Anthracyclines</title>
</titles>
<contributors>
<person_name sequence='first' contributor_role='author'>
<surname></surname>
</person_name>
</contributors>
<publication_date media_type='online'>
<year>2018</year>
</publication_date>
<doi_data>
<doi>10.15347/wjm/2018.001</doi>
<resource>https://en.wikiversity.org/wiki/WikiJournal of Medicine/Anthracyclines</resource>
</doi_data>
</journal_article>
</journal>
<article>
<permissions>
<license license-type="open-access">
<license-p>[[File:Open_Access_logo_PLoS_white.svg|11px|link=Wikipedia:Open Access]] [[File:Cc.logo.circle.svg|16px|link=Wikipedia:Creative Commons]]
This is an open access article distributed under the [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution License], which permits unrestricted use, distribution, and reproduction, provided the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
</p>
Anthracyclines are a clinically important class of antineoplastic agents used to treat a wide variety of solid and blood cancers. The first described anthracycline, daunorubicin, was first isolated from a strain of ''Streptomyces peucetius'' in the early 1960s. Clinically the most widely used are doxorubicin, daunorubicin and their semi-synthetic derivatives epirubicin and idarubicin. They primarily act by intercalating with DNA and inhibiting topoisomerase II, resulting in DNA breaks and abrogated DNA synthesis. The most serious side effect of anthracycline use is cumulative dose-dependent cardiotoxicity, limiting recommended maximum lifetime treatment to 400-450 mg/m<sup>2</sup>. Several liposomal formulations of doxorubicin are in use, having the benefits of prolonging retention rate while reducing peak plasma concentration of free drug. Several clinical trials of anthracycline-loaded nanoparticles are currently underway.
</p>
</abstract>
</article>
</body>
</doi_batch>
